Introduction: Indirect evidence suggests iGlarLixi is as efficacious as basal insulin (BI) + rapid acting insulin (RAI) for management of type 2 diabetes (T2D) . However, there are no direct comparisons of iGlarLixi (once-daily [QD]) vs. a BI+RAI regimen (multiple daily injections [MDI]) . SoliSimplify compared these treatments using real-world data from a US database.

Methods: Electronic medical records were analyzed retrospectively using propensity score matching (PSM) to compare therapy advancement with iGlarLixi or BI+RAI in adults ≥18 years with T2D on BI and ≥1 HbA1c available value at baseline and 6-month follow-up. The primary objective was non-inferiority of iGlarLixi to BI+RAI in HbA1c change from baseline to 6 months (margin 0.3 %) .

Results: PSM generated cohorts with balanced baseline characteristics (N=814 in each group; Table) . HbA1c reduction from baseline to 6 months with iGlarLixi was non-inferior to BI+RAI (p<0.025) . Weight gain was significantly lower with iGlarLixi than with BI+RAI (p<0.for the difference) . At 6 months, achievement of HbA1c <7 % without hypoglycemia and weight gain was similar between groups. Hypoglycemia was low in both groups, likely due to underreporting.

Conclusions: In this real-world study, QD iGlarLixi was as effective as MDI BI+RAI in HbA1c reduction and had a favorable body weight benefit.


R.J.Mccrimmon: Advisory Panel; Novo Nordisk, Sanofi, Research Support; Diabetes UK, European Union, MedImmune. A.Y.Cheng: Advisory Panel; Abbott, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, HLS Theraoeutics, Insulet Corporation, Janssen Pharmaceuticals, Inc., Medtronic, Novo Nordisk, Sanofi, Board Member; Type 1 Diabetes Think Tank Network, Other Relationship; Diabetes Canada, Speaker's Bureau; Bausch Health, Canada, Merck & Co., Inc. G.R.Galstyan: n/a. K.Djaballah: Employee; Sanofi. X.Li: Employee; Eisai Co., Ltd., Sanofi. M.Coudert: Employee; Sanofi. J.Frias: Advisory Panel; Altimmune, Becton, Dickinson and Company, Eli Lilly and Company, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi, Consultant; 89bio, Inc., Akero Therapeutics, Inc., Altimmune, Becton, Dickinson and Company, Carmot Therapeutics, Inc., Eli Lilly and Company, Novo Nordisk, Pfizer Inc., Sanofi, Research Support; Afimmune Limited, Akero Therapeutics, Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Carmot Therapeutics, Inc., Eli Lilly and Company, Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Janssen Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Poxel SA, Sanofi, Speaker's Bureau; Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at